FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE by Teva is clinical pharmacology mechanism of action fosinopril and fosinoprilat inhibit angiotensin-converting enzyme (ace) in human subjects and in animals. Approved for hypertension. First approved in 2006.
Drug data last refreshed 22h ago
CLINICAL PHARMACOLOGY Mechanism of Action Fosinopril and fosinoprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and in animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also…
Worked on FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.